Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00531622 · ClinicalTrials.gov registry record · Phase 3
An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 643
- Enrollment target
NCT00531622: Completed Phase 3 study, sponsored by Sanofi.
NCT00531622 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 643 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00531622, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 643 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the efficacy of saredutant 100mg once daily in combination with escitalopram 10mg once daily compared to saredutant placebo in combination with escitalopram 10mg once daily in patients with major depressive disorder. This study also includes a double-placebo group (saredutant placebo in combination with escitalopram placebo).
Interventions
- DRUG placebo
- DRUG escitalopram
- DRUG saredutant (SR48968)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 643 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-01 |
| Phase | Phase 3 |
What the finished NCT00531622 record still lists
NCT00531622 is an interventional study that assigns participants to a tested intervention. The registered 643 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% lower).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00531622 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00531622 about?
NCT00531622 is a clinical study titled "An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder". The main purpose of this study is to evaluate the efficacy of saredutant 100mg once daily in combination with escitalopram 10mg once daily compared to saredutant placebo in combination with escitalopram 10mg once daily in patients with major depressive disorder. This study also includes a double-pla...
What is the current status of trial NCT00531622?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 643 participants. The study started on 2007-09. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00531622?
The interventions under investigation include: placebo (DRUG), escitalopram (DRUG), saredutant (SR48968) (DRUG).
Who is sponsoring clinical trial NCT00531622?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00531622's enrollment target sits among peer trials
643 573rd of 2000 higher than 1,427 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05146297 · 644 participants · NA
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
- NCT06994442 · 644 participants · Phase 3
Optimizing Pain Treatment in Children On Mechanical Ventilation
- NCT05204888 · 642 participants · NA
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
- NCT07012395 · 645 participants · Phase 2
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia